A new Health Affairs blog suggests a handful of bipartisan drug-pricing reforms could move forward if House lawmakers agree to remove polarized Affordable Care Act reforms from the package. The blog says the following bipartisan ideas, in a less-polarized environment, could be advanced: “speeding access to generic drugs and correcting some of the anticompetitive practices in the industry, changing the PBM business model to operate on a flat-fee basis and share rebates fully with plans, and modifying the Part...